ECSP099656A - Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes - Google Patents
Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunesInfo
- Publication number
- ECSP099656A ECSP099656A EC2009009656A ECSP099656A ECSP099656A EC SP099656 A ECSP099656 A EC SP099656A EC 2009009656 A EC2009009656 A EC 2009009656A EC SP099656 A ECSP099656 A EC SP099656A EC SP099656 A ECSP099656 A EC SP099656A
- Authority
- EC
- Ecuador
- Prior art keywords
- antibodies
- present
- inflammatory
- treatment
- autoimmune diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
Abstract
La presente invención es concerniente con anticuerpos antagonistas dirigidos contra el receptor OX40 humano (CD 134) y fragmentos del mismo, en los que se incluyen las secuencias de aminoácidos de anticuerpos antagonistas y los ácidos nucleicos que codifican los anticuerpos. También incluidos en la presente invención se encuentran regiones de enlace de antígeno (CDR) derivadas de las regiones variables de cadena ligera y/o pesada de dichos anticuerpos. Otro aspecto de la presente invención es el uso de anticuerpos antagonistas anti-OX40 en el tratamiento de enfermedades inflamatorias y autoinmunes. La presente invención también es concerniente con secuencias humanizadas de un anticuerpo antagonista AlO y mapeo de epítopo del sitio de enlace del anticuerpo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90369307P | 2007-02-27 | 2007-02-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP099656A true ECSP099656A (es) | 2009-10-30 |
Family
ID=39620235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2009009656A ECSP099656A (es) | 2007-02-27 | 2009-09-25 | Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes |
Country Status (20)
Country | Link |
---|---|
US (1) | US20100136030A1 (es) |
EP (1) | EP2125891A2 (es) |
JP (1) | JP2010518873A (es) |
KR (1) | KR20100014588A (es) |
CN (1) | CN101668776A (es) |
AR (1) | AR065506A1 (es) |
AU (1) | AU2008219666A1 (es) |
BR (1) | BRPI0807269A2 (es) |
CA (1) | CA2679399A1 (es) |
CL (1) | CL2008000578A1 (es) |
CO (1) | CO6231009A2 (es) |
CR (1) | CR11042A (es) |
EC (1) | ECSP099656A (es) |
IL (1) | IL200572A0 (es) |
MA (1) | MA31246B1 (es) |
MX (1) | MX2009009194A (es) |
PE (1) | PE20090689A1 (es) |
RU (1) | RU2009135824A (es) |
TW (1) | TW200846367A (es) |
WO (1) | WO2008106116A2 (es) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7291331B1 (en) | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
KR20080080639A (ko) | 2005-12-16 | 2008-09-04 | 제넨테크, 인크. | 항-ox40l 항체 및 그의 사용 방법 |
MX2011007647A (es) * | 2009-01-21 | 2011-09-01 | Amgen Inc | Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes. |
CN102741287B (zh) * | 2009-02-17 | 2015-02-18 | Ucb制药公司 | 对人ox40具有特异性的抗体分子 |
ME02678B (me) | 2010-08-23 | 2017-06-20 | Univ Texas | Antitijela na ox-40 i postupci njihove primjene |
EP2731677B1 (en) * | 2011-07-11 | 2018-04-18 | Glenmark Pharmaceuticals S.A. | Antibodies that bind to ox40 and their uses |
AU2012299421B2 (en) * | 2011-08-23 | 2016-02-04 | Board Of Regents, The University Of Texas System | Anti-OX40 antibodies and methods of using the same |
GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
UA112203C2 (uk) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
MX2015003416A (es) * | 2012-09-17 | 2015-10-29 | Galectin Therapeutics Inc | Metodo para mejorar las inmunoterapias especificas en el tratamiento contra el cancer. |
NZ712903A (en) | 2013-03-18 | 2018-07-27 | Biocerox Prod Bv | Humanized anti-cd134 (ox40) antibodies and uses thereof |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
AU2015246037B2 (en) | 2014-04-11 | 2018-04-12 | Novartis Ag | Methods of selectively treating asthma using IL-13 antagonists |
CN108064242B (zh) | 2014-05-28 | 2022-10-21 | 阿吉纳斯公司 | 抗gitr抗体和其使用方法 |
US11111284B2 (en) | 2014-08-21 | 2021-09-07 | The General Hospital Corporation | Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing |
TW201619200A (zh) * | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗-ox40抗體及其用途 |
ES2922398T3 (es) | 2015-01-08 | 2022-09-14 | BioNTech SE | Agentes agonistas de unión al receptor de TNF |
US9512229B2 (en) | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
ES2937020T3 (es) | 2015-03-03 | 2023-03-23 | Kymab Ltd | Anticuerpos, usos y métodos |
JP2018512397A (ja) * | 2015-03-11 | 2018-05-17 | プロビデンス ヘルス アンド サービシーズ−オレゴン | 癌治療の有効性を高めるための組成物及び方法 |
US10293059B2 (en) | 2015-04-09 | 2019-05-21 | Cornell University | Gene therapy to prevent reactions to allergens |
US10851144B2 (en) | 2015-04-10 | 2020-12-01 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
EP3292152A1 (en) | 2015-05-07 | 2018-03-14 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
JP6797137B2 (ja) | 2015-05-29 | 2020-12-09 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Ox40に対する抗体およびその使用 |
WO2017046746A1 (en) | 2015-09-15 | 2017-03-23 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist |
CA2999369C (en) * | 2015-09-22 | 2023-11-07 | Spring Bioscience Corporation | Anti-ox40 antibodies and diagnostic uses thereof |
CN114380908B (zh) * | 2015-10-15 | 2023-03-17 | 苏州丁孚靶点生物技术有限公司 | 抗ox40抗体及其应用 |
WO2017096179A1 (en) * | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
WO2017134292A1 (en) * | 2016-02-04 | 2017-08-10 | Glenmark Pharmaceuticals S.A. | Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis |
AU2017281830B2 (en) | 2016-06-20 | 2023-04-06 | Kymab Limited | Anti-PD-L1 antibodies |
TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
WO2018089628A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
US11117963B2 (en) * | 2016-12-26 | 2021-09-14 | Kyowa Hakko Kirin Co., Ltd. | Antibody which binds to myelin oligodendrocyte glycoprotein |
BR112019013463A2 (pt) | 2016-12-29 | 2020-01-07 | University Of Miami | Método para a modulação da atividade de inflamassoma e da inflamação nos pulmões |
US11840565B2 (en) | 2016-12-29 | 2023-12-12 | University Of Miami | Methods and compositions for treating virus-associated inflammation |
CN110462027A (zh) | 2017-01-06 | 2019-11-15 | 艾欧凡斯生物治疗公司 | 用肿瘤坏死因子受体超家族(tnfrsf)激动剂扩增肿瘤浸润淋巴细胞(til)及til和tnfrsf激动剂的治疗组合 |
SG10202108899XA (en) * | 2017-02-23 | 2021-09-29 | Zeria Pharmaceutical Co Ltd | Anti-inflammatory agent |
CN108623686A (zh) * | 2017-03-25 | 2018-10-09 | 信达生物制药(苏州)有限公司 | 抗ox40抗体及其用途 |
AR112072A1 (es) | 2017-06-05 | 2019-09-18 | Iovance Biotherapeutics Inc | Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario |
WO2019100023A1 (en) | 2017-11-17 | 2019-05-23 | Iovance Biotherapeutics, Inc. | Til expansion from fine needle aspirates and small biopsies |
AU2019205823A1 (en) | 2018-01-08 | 2020-07-30 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
WO2019136459A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
MA51875A (fr) | 2018-02-13 | 2020-12-23 | Iovance Biotherapeutics Inc | Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine |
WO2019210131A1 (en) | 2018-04-27 | 2019-10-31 | Iovance Biotherapeutics, Inc. | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
KR20210071944A (ko) * | 2018-07-03 | 2021-06-16 | 더 유니버시티 오브 마이애미 | 인플라마솜 관련 질환 또는 상태 치료용 조성물 및 방법 |
TW202031273A (zh) | 2018-08-31 | 2020-09-01 | 美商艾歐凡斯生物治療公司 | 抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療 |
IL281423B1 (en) | 2018-09-20 | 2024-04-01 | Iovance Biotherapeutics Inc | Expansion of TILS from cryopreserved tumor samples |
CN112513088B (zh) * | 2018-09-26 | 2023-05-16 | 江苏恒瑞医药股份有限公司 | 抗ox40抗体、其抗原结合片段及其医药用途 |
CA3118634A1 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients refractory for anti-pd-1 antibody |
SG11202104615VA (en) | 2018-11-05 | 2021-06-29 | Iovance Biotherapeutics Inc | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
CA3118493A1 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Expansion of tils utilizing akt pathway inhibitors |
US20230039976A1 (en) | 2018-11-05 | 2023-02-09 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
EP3885365A1 (en) * | 2018-11-20 | 2021-09-29 | Shanghai Pharmaexplorer Co., Ltd. | Ox40 antibody, preparation method thereof and use thereof |
CN109651510B (zh) * | 2018-12-04 | 2023-03-24 | 上海长征医院 | 抗Eno1抗体及其用途 |
EP3898949A1 (en) | 2018-12-19 | 2021-10-27 | Iovance Biotherapeutics, Inc. | Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof |
WO2020160489A1 (en) * | 2019-02-01 | 2020-08-06 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
AU2020256125A1 (en) | 2019-03-29 | 2021-11-18 | Turnstone Biologics Corp. | Ex vivo methods for producing a T cell therapeutic and related compositions and methods |
US20220249559A1 (en) | 2019-05-13 | 2022-08-11 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
JP2022553389A (ja) | 2019-10-25 | 2022-12-22 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 腫瘍浸潤リンパ球の遺伝子編集及び免疫療法におけるその使用 |
AU2020391231A1 (en) | 2019-11-27 | 2022-07-14 | Turnstone Biologics Corp. | Method of producing tumor-reactive T cell composition using modulatory agents |
JP2023506734A (ja) | 2019-12-11 | 2023-02-20 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 腫瘍浸潤リンパ球(til)の産生のためのプロセス及びそれを使用する方法 |
MX2022010517A (es) | 2020-02-27 | 2022-11-14 | Myst Therapeutics Llc | Metodos para la expansion y enriquecimiento ex vivo de celulas t reactivas a tumor y composiciones relacionadas de las mismas. |
US20230293685A1 (en) | 2020-05-04 | 2023-09-21 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
TW202208617A (zh) | 2020-05-04 | 2022-03-01 | 美商艾歐凡斯生物治療公司 | 用於產生腫瘤浸潤性淋巴球的過程及其在免疫療法中的用途 |
WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
JP2023546359A (ja) | 2020-10-06 | 2023-11-02 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 腫瘍浸潤リンパ球療法によるnsclc患者の治療 |
CN116368154A (zh) | 2020-10-08 | 2023-06-30 | 阿菲姆德股份有限公司 | 三特异性结合剂 |
TW202241468A (zh) | 2020-12-11 | 2022-11-01 | 美商艾歐凡斯生物治療公司 | 用腫瘤浸潤性淋巴球療法與braf抑制劑及/或mek抑制劑組合治療癌症患者 |
AU2021401302A1 (en) | 2020-12-17 | 2023-07-06 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
US20240123067A1 (en) | 2020-12-17 | 2024-04-18 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocyte therapies |
AU2022263418A1 (en) | 2021-04-19 | 2023-10-26 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
EP4377446A1 (en) | 2021-07-28 | 2024-06-05 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
WO2023007023A1 (en) | 2021-07-30 | 2023-02-02 | Affimed Gmbh | Duplexbodies |
TW202331735A (zh) | 2021-10-27 | 2023-08-01 | 美商艾歐凡斯生物治療公司 | 協調用於患者特異性免疫療法之細胞之製造的系統及方法 |
AU2022388729A1 (en) | 2021-11-10 | 2024-05-16 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
WO2023147486A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
WO2023201369A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
WO2024030758A1 (en) | 2022-08-01 | 2024-02-08 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
WO2024056861A1 (en) | 2022-09-15 | 2024-03-21 | Avidicure Ip B.V. | Multispecific antigen binding proteins for stimulating nk cells and use thereof |
WO2024151885A1 (en) | 2023-01-13 | 2024-07-18 | Iovance Biotherapeutics, Inc. | Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5821332A (en) * | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
US5759546A (en) * | 1994-02-04 | 1998-06-02 | Weinberg; Andrew D. | Treatment of CD4 T-cell mediated conditions |
US6057421A (en) * | 1994-11-30 | 2000-05-02 | Immpheron, Inc. | Variable heavy and light chain regions of murine monoclonal antibody 1F7 |
WO2003106498A2 (en) * | 2002-06-13 | 2003-12-24 | Crucell Holland, B.V. | Agonistic binding molecules to the human ox40 receptor |
PL376536A1 (pl) * | 2002-08-28 | 2006-01-09 | Immunex Corporation | Kompozycje i sposoby leczenia chorób układu sercowo-naczyniowego |
ATE452147T1 (de) * | 2004-02-19 | 2010-01-15 | Genentech Inc | Antikörper mit korrigierten cdr |
JP5838021B2 (ja) * | 2005-04-15 | 2015-12-24 | マクロジェニクス,インコーポレーテッド | 共有結合型ダイアボディとその使用 |
TWI461436B (zh) * | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類cd134(ox40)之人類單株抗體及其製造及使用方法 |
KR20080080639A (ko) * | 2005-12-16 | 2008-09-04 | 제넨테크, 인크. | 항-ox40l 항체 및 그의 사용 방법 |
-
2008
- 2008-02-26 RU RU2009135824/10A patent/RU2009135824A/ru not_active Application Discontinuation
- 2008-02-26 MX MX2009009194A patent/MX2009009194A/es unknown
- 2008-02-26 KR KR1020097020065A patent/KR20100014588A/ko not_active Application Discontinuation
- 2008-02-26 JP JP2009551698A patent/JP2010518873A/ja not_active Withdrawn
- 2008-02-26 CL CL200800578A patent/CL2008000578A1/es unknown
- 2008-02-26 AU AU2008219666A patent/AU2008219666A1/en not_active Abandoned
- 2008-02-26 EP EP08726081A patent/EP2125891A2/en not_active Withdrawn
- 2008-02-26 CN CN200880013914A patent/CN101668776A/zh active Pending
- 2008-02-26 US US12/526,550 patent/US20100136030A1/en not_active Abandoned
- 2008-02-26 CA CA002679399A patent/CA2679399A1/en not_active Abandoned
- 2008-02-26 BR BRPI0807269-8A2A patent/BRPI0807269A2/pt not_active IP Right Cessation
- 2008-02-26 WO PCT/US2008/002498 patent/WO2008106116A2/en active Application Filing
- 2008-02-27 TW TW097106870A patent/TW200846367A/zh unknown
- 2008-02-27 AR ARP080100818A patent/AR065506A1/es unknown
- 2008-02-27 PE PE2008000393A patent/PE20090689A1/es not_active Application Discontinuation
-
2009
- 2009-08-25 IL IL200572A patent/IL200572A0/en unknown
- 2009-09-10 MA MA32212A patent/MA31246B1/fr unknown
- 2009-09-23 CO CO09103883A patent/CO6231009A2/es not_active Application Discontinuation
- 2009-09-24 CR CR11042A patent/CR11042A/es unknown
- 2009-09-25 EC EC2009009656A patent/ECSP099656A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2008000578A1 (es) | 2008-10-10 |
CO6231009A2 (es) | 2010-12-20 |
KR20100014588A (ko) | 2010-02-10 |
CN101668776A (zh) | 2010-03-10 |
IL200572A0 (en) | 2010-05-17 |
MX2009009194A (es) | 2009-10-08 |
MA31246B1 (fr) | 2010-03-01 |
EP2125891A2 (en) | 2009-12-02 |
RU2009135824A (ru) | 2011-04-10 |
US20100136030A1 (en) | 2010-06-03 |
WO2008106116A2 (en) | 2008-09-04 |
WO2008106116A3 (en) | 2008-10-16 |
JP2010518873A (ja) | 2010-06-03 |
AR065506A1 (es) | 2009-06-10 |
CA2679399A1 (en) | 2008-09-04 |
AU2008219666A1 (en) | 2008-09-04 |
BRPI0807269A2 (pt) | 2014-04-29 |
TW200846367A (en) | 2008-12-01 |
PE20090689A1 (es) | 2009-06-20 |
CR11042A (es) | 2009-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP099656A (es) | Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes | |
CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
CY1123145T1 (el) | Anti-cd40 αντισωματα | |
CY1117124T1 (el) | ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ | |
PE20131403A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
PE20110668A1 (es) | Anticuerpos anti-linfopoyetina estromal timica (anti-tslp) | |
EA201991577A1 (ru) | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер | |
PE20091196A1 (es) | Anticuerpos contra el vegf completamente humano, composiciones y metodos | |
PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
CY1115572T1 (el) | Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου | |
EA201591091A1 (ru) | Антигенсвязывающие белки для bcma | |
EA201690325A1 (ru) | БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ Fc-ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬ CD32B И CD79b, И ИХ ПРИМЕНЕНИЯ | |
AR070346A1 (es) | Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos | |
CO6231038A2 (es) | Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos | |
PE20090294A1 (es) | Composicion farmaceutica que comprende un antagonista del factor d y su uso en el tratamiento de condiciones oculares | |
EA201070888A1 (ru) | Антитела и их производные | |
UY32752A (es) | Polipéptidos y Métodos de Tratamiento | |
PE20211293A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
UY36942A (es) | Proteínas de unión a antígeno que activan el receptor de leptina | |
JP2017508475A5 (es) | ||
EA201592285A1 (ru) | Антигенсвязывающие белки к рецептору онкостатина м | |
CY1115349T1 (el) | Εξανθρωπισμενα αντι cxcr4 αντισωματα για τη θεραπεια καρκινου | |
EA202091747A1 (ru) | Составы антитела b7-h4 |